The first-in-human Phase-I clinical trial for gene therapy of Hemophilia A has shown clinically significant outcomes.

Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) have developed a ...

Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, and Viralgen, a leading contract development and manufacturing organization ...

Belief BioMed ("BBM") today announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the Pharmaceutical Administration Bureau of Macao Special ...

SHANGHAI, March 19, 2026 /PRNewswire/ -- Belief BioMed ("BBM") today announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the Pharmaceutical ...

He is the first person in the state to receive LYFGENIA, a one-time gene therapy designed to keep the red blood cells that ...

In this study, researchers aimed to characterize the mutational landscape of the tumors of domestic cats to determine whether similarities to humans could translate to the clinic.

India has introduced national guidelines to ensure the safe and ethical use of CRISPR-based therapies, while stepping up efforts to build domestic capabilities in gene editing and advanced ...

Regulatory bodies have issued national guidelines to ensure safe, ethical deployment of CRISPR-based therapies in India, while the BioE3 is accelerating indigenous capacity for cell and gene ...

Gene and cell therapy is moving fast – and in a clear direction. Programs are pushing toward more complex payloads, virus-free engineering, and manufacturing models that can scale from early research ...

New research shows epigenetic silencing may limit durability of AAV gene therapy in haemophilia by reducing long term transgene expression in liver cells.